Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).
Bin GaoWeiguo GaoHailong WanFengmei XuRong ZhouXia ZhangQiuhe JiPublished in: Diabetes, obesity & metabolism (2022)
Glycaemic control was comparable between alogliptin and acarbose, but the gastrointestinal tolerability of alogliptin was better. More patients achieved target HbA1c without gastrointestinal AEs with alogliptin, suggesting that this agent may be preferred in clinical practice.
Keyphrases
- open label
- type diabetes
- clinical trial
- phase iii
- double blind
- phase ii
- study protocol
- end stage renal disease
- clinical practice
- newly diagnosed
- phase ii study
- chronic kidney disease
- ejection fraction
- placebo controlled
- low dose
- insulin resistance
- prognostic factors
- cardiovascular disease
- radiation therapy
- peritoneal dialysis
- emergency department
- metabolic syndrome
- cross sectional
- acute coronary syndrome
- adipose tissue
- rectal cancer
- patient reported outcomes
- combination therapy